Anthem Biosciences Complete Financial Statements

In FY2025, Anthem Biosciences (ANTHEM) reported revenue ₹598 Cr, net profit ₹173 Cr and EPS ₹3.09, with a net profit margin of 28.9% and ROE of 7.2%. Full financial statements from FY2020 to FY2025 (6 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Anthem Biosciences share price chart.

6 Years of Data
2025 - 2020

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 28.93% 2025 data
EBITDA Margin 44.48% 2025 data
Operating Margin 40.00% 2025 data
Return on Assets 6.16% 2025 data
Return on Equity 7.18% 2025 data

Balance Sheet Ratios

Current Ratio 24.13 2025 data
Equity Ratio 85.83% 2025 data
Asset Turnover 0.21 2025 data

ANTHEM Revenue, Net Profit & EBITDA — Year-on-Year Growth

ANTHEM YoY (Sept 2024 vs Sept 2025) — revenue +8.1%, net profit +6.8%, EBITDA +19.3%, expenses +0.6%.

Revenue Growth
+8.1%
Year-over-Year
Net Profit Growth
+6.8%
Year-over-Year
EBITDA Growth
+19.3%
Year-over-Year
Expense Growth
+0.6%
Year-over-Year
Assets Growth
+17.1%
Year-over-Year
Equity Growth
+25.2%
Year-over-Year
Operating Cash Flow Growth
+198.6%
Year-over-Year
Investing Cash Flow Growth
+31.5%
Year-over-Year
Financing Cash Flow Growth
-74.0%
Year-over-Year

ANTHEM Income Statement — Revenue, EBITDA & Net Profit

Anthem Biosciences revenue ₹598 Cr, EBITDA ₹266 Cr, net profit ₹173 Cr, EPS ₹3.09 (2025) — net profit margin 28.9%. Explore ANTHEM investment value to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Jun 2024 Dec 2024
Revenue 598 497 563 457 553 358 522
Expenses 332 288 349 291 330 218 338
EBITDA 266 209 214 165 223 140 184
Operating Profit Margin % 40.00% 40.00% 35.00% 31.00% 37.00% 36.00% 32.00%
Depreciation 34 30 27 35 20 19 20
Interest 3 1 2 0 4 4 3
Profit Before Tax 230 178 186 131 200 118 161
Tax 56 96 51 38 38 36 37
Net Profit 173 83 136 93 162 82 124
Earnings Per Share (₹) 3.09 1.48 2.43 1.65 2.90 1.47 2.22

ANTHEM Balance Sheet — Assets, Liabilities & Shareholders' Equity

ANTHEM total assets ₹2,808 Cr, total equity ₹2,410 Cr, total liabilities ₹ Cr (2025) — ROE 7.2%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020
ASSETS
Total Assets 2,808 2,398 2,015 1,619 1,034 787
Current Assets 1,737 1,482 1,323 1,098 616 403
Fixed Assets 705 483 449 329 361 306
Capital Work in Progress 297 345 164 154 19 50
Investments 433 472 499 273 209 99
Other Assets 1,373 1,099 903 863 445 333
LIABILITIES
Total Liabilities
Current Liabilities 72 135 110 41 47 118
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 2,410 1,925 1,741 1,355 702 422
Share Capital 112 112 114 9 9 8
Reserves & Surplus 2,298 1,813 1,627 1,346 693 414

ANTHEM Cash Flow Statement — Operating, Investing & Financing

Anthem Biosciences operating cash flow ₹418 Cr, investing ₹-152 Cr, financing ₹-134 Cr, net cash flow ₹133 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020
Operating Activities 418 140 306 333 278 166
Investing Activities -152 -222 -376 -205 -196 -109
Financing Activities -134 -77 64 181 -63 -48
Net Cash Flow 133 -159 -6 308 18 9